These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 25271622)

  • 1. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
    Dubovsky JA; Flynn R; Du J; Harrington BK; Zhong Y; Kaffenberger B; Yang C; Towns WH; Lehman A; Johnson AJ; Muthusamy N; Devine SM; Jaglowski S; Serody JS; Murphy WJ; Munn DH; Luznik L; Hill GR; Wong HK; MacDonald KK; Maillard I; Koreth J; Elias L; Cutler C; Soiffer RJ; Antin JH; Ritz J; Panoskaltsis-Mortari A; Byrd JC; Blazar BR
    J Clin Invest; 2014 Nov; 124(11):4867-76. PubMed ID: 25271622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
    Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
    PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
    Miklos D; Cutler CS; Arora M; Waller EK; Jagasia M; Pusic I; Flowers ME; Logan AC; Nakamura R; Blazar BR; Li Y; Chang S; Lal I; Dubovsky J; James DF; Styles L; Jaglowski S
    Blood; 2017 Nov; 130(21):2243-2250. PubMed ID: 28924018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
    Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
    Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
    Rahmat LT; Logan AC
    Drugs Today (Barc); 2018 May; 54(5):305-313. PubMed ID: 29911695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Waller EK; Miklos D; Cutler C; Arora M; Jagasia MH; Pusic I; Flowers MED; Logan AC; Nakamura R; Chang S; Clow F; Lal ID; Styles L; Jaglowski S
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2002-2007. PubMed ID: 31260802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
    Palaniyandi S; Strattan E; Kumari R; Mysinger M; Hakim N; Kesler MV; Apatira M; Bittencourt F; Wang L; Jia Z; Gururaja TL; Hill RJ; Hildebrandt GC
    Bone Marrow Transplant; 2023 Aug; 58(8):924-935. PubMed ID: 37160943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
    Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
    Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review.
    Santosa D; Rizky D; Tandarto K; Kartiyani I; Yunarvika V; Ardini DNE; Setiawan B; Pangarsa EA; Suharti C
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4025-4033. PubMed ID: 38156834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
    Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
    Jaglowski SM; Blazar BR
    Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study.
    Carpenter PA; Kang HJ; Yoo KH; Zecca M; Cho B; Lucchini G; Nemecek ER; Schultz KR; Stepensky P; Chaudhury S; Oshrine B; Khaw SL; Harris AC; Verna M; Zubarovskaya L; Lee Y; Wahlstrom J; Styles L; Shaw PJ; Dalle JH
    Transplant Cell Ther; 2022 Nov; 28(11):771.e1-771.e10. PubMed ID: 36044977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
    Kokhaei P; Jadidi-Niaragh F; Sotoodeh Jahromi A; Osterborg A; Mellstedt H; Hojjat-Farsangi M
    J Drug Target; 2016; 24(5):373-85. PubMed ID: 26362595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease.
    Thangavelu G; Zaiken MC; Mohamed FA; Flynn R; Du J; Rhee SY; Riddle MJ; Aguilar EG; Panoskaltsis-Mortari A; Sanders ME; Blazar BR
    Front Immunol; 2022; 13():765319. PubMed ID: 35359939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
    Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
    Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.
    Radojcic V; Paz K; Chung J; Du J; Perkey ET; Flynn R; Ivcevic S; Zaiken M; Friedman A; Yan M; Pletneva MA; Sarantopoulos S; Siebel CW; Blazar BR; Maillard I
    Blood; 2018 Nov; 132(20):2188-2200. PubMed ID: 30181175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Dubovsky JA; Beckwith KA; Natarajan G; Woyach JA; Jaglowski S; Zhong Y; Hessler JD; Liu TM; Chang BY; Larkin KM; Stefanovski MR; Chappell DL; Frissora FW; Smith LL; Smucker KA; Flynn JM; Jones JA; Andritsos LA; Maddocks K; Lehman AM; Furman R; Sharman J; Mishra A; Caligiuri MA; Satoskar AR; Buggy JJ; Muthusamy N; Johnson AJ; Byrd JC
    Blood; 2013 Oct; 122(15):2539-49. PubMed ID: 23886836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
    Flynn R; Paz K; Du J; Reichenbach DK; Taylor PA; Panoskaltsis-Mortari A; Vulic A; Luznik L; MacDonald KK; Hill GR; Nyuydzefe MS; Weiss JM; Chen W; Trzeciak A; Serody JS; Aguilar EG; Murphy WJ; Maillard I; Munn D; Koreth J; Cutler CS; Antin JH; Ritz J; Waksal SD; Zanin-Zhorov A; Blazar BR
    Blood; 2016 Apr; 127(17):2144-54. PubMed ID: 26983850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.